Pharmaceutical Markets and Insurance Worldwide

Michael Grossman|Björn Lindgren

Emerald

This book can be opened with

Hardback

9781849507165

30 March 2010

£112.99

eBook (PDF)

9781849507172

30 March 2010

£108.99

Note on our eBooks and Audiobooks: you can read our eBooks (ePUB or PDF) and listen to audiobooks on the free Emerald Books app on iOS, Android, and desktop. Or read and listen on Emerald's online reader (ePUB eBooks and audiobooks only). To purchase a digital book you will need to create an account if you don’t already have one. After purchasing you will receive instructions on how to get started.

Description
Contents

The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries.

List of Contributors. Overview. Pharmaceutical policies in European countries. International experience with comparative effectiveness research: Case studies from England/Wales and Germany. Pharmaceutical policy in the Netherlands: From price regulation towards managed competition. Impact of pharmaceutical regulation and policies on health system performance goals in Israel. Global budgets and provider incentives: Hospitals’ drug expenditures in Taiwan. Medicare Part D turns four: Trends in plan design, enrollment, and the impact of the program on beneficiaries. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. cost sharing, benefit design, and adherence: The case of multiple sclerosis. Generic utilization and cost-sharing for prescription drugs. Drug prices, out-of-pocket payments, and insurer costs: How do payers vary?. Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions. The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the medicare part D era. Patents, innovation, and the welfare effects of Medicare Part D. Advances in health economics and health services research. Pharmaceutical Markets and Insurance Worldwide. Copyright page.